Pineoblastoma segregates into molecular sub-groups with distinct clinicopathologic features: A Rare Brain Tumor Consortium registry study

Pineoblastoma (PB) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta neuropathologica 2019-12, Vol.139 (2), p.223-241
Hauptverfasser: Li, Bryan K, Vasiljevic, Alexandre, Dufour, Christelle, Yao, Fupan, Ho, Ben LB, Lu, Mei, Hwang, Eugene I, Gururangan, Sridharan, Hansford, Jordan R, Fouladi, Maryam, Nobusawa, Sumihito, Laquerriere, Annie, Delisle, Marie-Bernadette, Fangusaro, Jason, Forest, Fabien, Toledano, Helen, Solano-Paez, Palma, Leary, Sarah, Birks, Diane, Hoffman, Lindsey M, Szathmari, Alexandru, Faure-Conter, Cécile, Fan, Xing, Catchpoole, Daniel, Zhou, Li, Schultz, Kris Ann P, Ichimura, Koichi, Gauchotte, Guillaume, Jabado, Nada, Jones, Chris, Loussouarn, Delphine, Mokhtari, Karima, Rousseau, Audrey, Ziegler, David S, Tanaka, Shinya, Pomeroy, Scott L., Gajjar, Amar, Ramaswamy, Vijay, Hawkins, Cynthia, Grundy, Richard G, Hill, D Ashley, Bouffet, Eric, Huang, Annie, Jouvet, Anne
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pineoblastoma (PB) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment approaches for this orphan cancer. Tumor, blood, and clinical data from 91 patients with PB or supratentorial primitive neuroectodermal tumor (sPNETs/CNS-PNETs), and 2 pineal parenchymal tumors of intermediate differentiation (PPTIDs) were collected from 29 centres in the Rare Brain Tumor Consortium. We used global DNA methylation profiling to define a core group of PB from 72/93 cases, which were delineated into five molecular subgroups. Copy number, whole exome and targeted sequencing, and miRNA expression analyses were used to evaluate the clinico-pathologic significance of each subgroup. Tumors designated as group 1 and 2 almost exclusively exhibited deleterious homozygous loss of function alterations in miRNA biogenesis genes ( DICER1 , DROSHA , and DGCR8 ) in 62 and 100% of group 1 and 2 tumors respectively. Recurrent alterations of the oncogenic MYC-miR-17/92-RB1 pathway were observed in the RB and MYC subgroup, respectively characterized by RB1 loss with gain of miR-17/92 , and recurrent gain or amplification of MYC . PB sub-groups exhibited distinct clinical features: group 1-3 arose in older children (median ages 5.2-14.0 years) and had intermediate to excellent survival (5-year OS of 68.0-100%), while Group RB and MYC PB patients were much younger (median age 1.3-1.4 years) with dismal survival (5-year OS 37.5% and 28.6%, respectively). We identified age
ISSN:0001-6322
1432-0533
DOI:10.1007/s00401-019-02111-y